Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)
Glaucoma is a group of eye diseases which result in damage to the optic nerve and vision loss. The most common type is open-angle glaucoma with less common types including closed-angle glaucoma and normal-tension glaucoma. Open-angle glaucoma develops slowly over time and there is no pain. Side vision may begin to decrease followed by central vision resulting in blindness, if not treated. Closed-angle glaucoma can present gradually or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea. Vision loss from glaucoma, once it has occurred, is permanent.
Though, glaucoma cannot be cured completely but the disease progression can be controlled with the help of available treatments. There are three types of modalities available for treatment of glaucoma: Drugs, Laser and Invasive Surgery. Further, based upon the approaches employed for the medication, it can be segmented into two parts: PGA Medication and Non-PGA Medication. The PGA approach reduces IOP with the help of prostaglandin (PGA). The non-PGA medication can be further divided into four sub segments: Beta blockers, Alpha blockers, Carbonic anhydrase inhibitors (CAIs) and Combination Products.
Several factors such as rising prevalence of diabetes, growing geriatric population and rising health care expenditure along with increasing disposable income and growing obese population will drive the market growth in the next few years. Development of new drugs & devices and drug therapy focused upon IOP are the few notable market trends. However, high cost of treatment, severe side effects and hasty drug approval processes act as a major roadblock for the market growth.
The report “Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)” analyzes the development of this market, with focus on the US and OUS treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Pfizer Inc., Novartis AG, Merck & Co., Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global glaucoma market along with the study of the US market.
Though, glaucoma cannot be cured completely but the disease progression can be controlled with the help of available treatments. There are three types of modalities available for treatment of glaucoma: Drugs, Laser and Invasive Surgery. Further, based upon the approaches employed for the medication, it can be segmented into two parts: PGA Medication and Non-PGA Medication. The PGA approach reduces IOP with the help of prostaglandin (PGA). The non-PGA medication can be further divided into four sub segments: Beta blockers, Alpha blockers, Carbonic anhydrase inhibitors (CAIs) and Combination Products.
Several factors such as rising prevalence of diabetes, growing geriatric population and rising health care expenditure along with increasing disposable income and growing obese population will drive the market growth in the next few years. Development of new drugs & devices and drug therapy focused upon IOP are the few notable market trends. However, high cost of treatment, severe side effects and hasty drug approval processes act as a major roadblock for the market growth.
The report “Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)” analyzes the development of this market, with focus on the US and OUS treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Pfizer Inc., Novartis AG, Merck & Co., Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global glaucoma market along with the study of the US market.
1. OVERVIEW
1.1 Glaucoma
1.2 Causes & Types
1.3 Symptoms & Diagnosis
1.4 Treatment Methods
1.5 Glaucoma Pharmaceutical Market Segmentation
2. GLOBAL GLAUCOMA MARKET
2.1 Global Glaucoma Market Forecast by Value
2.2 Global Glaucoma Market by Segments
2.3 Global Glaucoma Drugs Market Forecast by Value
2.4 Global Glaucoma Market by Drug Class
2.5 Global Glaucoma Drugs Market by Region
2.6 Global Glaucoma Patient Volume Forecast
3. REGIONAL MARKETS
3.1 The US
3.1.1 The US Glaucoma Drugs Market Forecast by Value
3.1.2 The US Glaucoma Patient Volume Forecast
3.1.3 The US Open Angle Glaucoma Patient Volume Forecast
3.1.4 The US Glaucoma Prescription Volume Forecast
3.1.5 The US Glaucoma Drugs Market by Type
3.1.6 The US Glaucoma First Line Drugs Market Forecast by Value
3.1.7 The US Glaucoma First Line Drugs Prescription Volume Forecast
3.1.8 The US Glaucoma Second Line Drugs Market Forecast by Value
3.1.9 The US Glaucoma Second Line Drugs Prescription Volume Forecast
3.1.10 The US MIGS Procedure Volume Forecast
3.2 The OUS
3.2.1 OUS Glaucoma Drugs Market Forecast by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Prevalence of Diabetes
4.1.2 Growing Geriatric Population
4.1.3 Rising Healthcare Expenditure
4.1.4 Rising Disposable Income
4.1.5 Growing Obese Population
4.2 Key Trends & Development
4.2.1 Development of New Drugs and Therapies
4.2.2 Drug Therapies Target Intraocular Pressure
4.3 Challenges
4.3.1 High Cost
4.3.2 Side Effects
4.3.3 Hasty Drug Approval Process
5. COMPETITIVE LANDSCAPE
5.1 Global Glaucoma Market
5.1.1 Global Glaucoma Market- Key Companies Revenue & Market Cap Comparison
5.2 The US
5.2.1 The US Glaucoma First Line Drugs Market Share by Company
5.2.2 The US Glaucoma Second Line Drugs Market Share by Company
5.2.3 The US MIGS Market Share by Company
6. COMPANY PROFILES
6.1 Pfizer Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Novartis AG
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Merck & Co., Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Allergan Plc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Glaucoma
1.2 Causes & Types
1.3 Symptoms & Diagnosis
1.4 Treatment Methods
1.5 Glaucoma Pharmaceutical Market Segmentation
2. GLOBAL GLAUCOMA MARKET
2.1 Global Glaucoma Market Forecast by Value
2.2 Global Glaucoma Market by Segments
2.3 Global Glaucoma Drugs Market Forecast by Value
2.4 Global Glaucoma Market by Drug Class
2.5 Global Glaucoma Drugs Market by Region
2.6 Global Glaucoma Patient Volume Forecast
3. REGIONAL MARKETS
3.1 The US
3.1.1 The US Glaucoma Drugs Market Forecast by Value
3.1.2 The US Glaucoma Patient Volume Forecast
3.1.3 The US Open Angle Glaucoma Patient Volume Forecast
3.1.4 The US Glaucoma Prescription Volume Forecast
3.1.5 The US Glaucoma Drugs Market by Type
3.1.6 The US Glaucoma First Line Drugs Market Forecast by Value
3.1.7 The US Glaucoma First Line Drugs Prescription Volume Forecast
3.1.8 The US Glaucoma Second Line Drugs Market Forecast by Value
3.1.9 The US Glaucoma Second Line Drugs Prescription Volume Forecast
3.1.10 The US MIGS Procedure Volume Forecast
3.2 The OUS
3.2.1 OUS Glaucoma Drugs Market Forecast by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Prevalence of Diabetes
4.1.2 Growing Geriatric Population
4.1.3 Rising Healthcare Expenditure
4.1.4 Rising Disposable Income
4.1.5 Growing Obese Population
4.2 Key Trends & Development
4.2.1 Development of New Drugs and Therapies
4.2.2 Drug Therapies Target Intraocular Pressure
4.3 Challenges
4.3.1 High Cost
4.3.2 Side Effects
4.3.3 Hasty Drug Approval Process
5. COMPETITIVE LANDSCAPE
5.1 Global Glaucoma Market
5.1.1 Global Glaucoma Market- Key Companies Revenue & Market Cap Comparison
5.2 The US
5.2.1 The US Glaucoma First Line Drugs Market Share by Company
5.2.2 The US Glaucoma Second Line Drugs Market Share by Company
5.2.3 The US MIGS Market Share by Company
6. COMPANY PROFILES
6.1 Pfizer Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Novartis AG
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Merck & Co., Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Allergan Plc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Types of Glaucoma
Treatments Available for Glaucoma
Glaucoma Pharmaceutical Market by Segment
Global Glaucoma Market Forecast by Value (2016-2021)
Global Glaucoma Market by Segments (2016)
Global Glaucoma Drugs Market Forecast by Value (2016-2021)
Global Glaucoma Market by Drug Class (2016)
Global Glaucoma Drugs Market by Region (2016)
Global Glaucoma Patient Volume Forecast (2016-2021)
The US Glaucoma Drugs Market Forecast by Value (2016-2021)
The US Glaucoma Patient Volume Forecast (2016-2021)
The US Open Angle Glaucoma Patient Volume Forecast (2016-2021)
The US Glaucoma Prescription Volume Forecast (2016-2021)
The US Glaucoma Drug Market by Type (2016)
The US Glaucoma First Line Drugs Market Forecast by Value (2016-2021)
The US Glaucoma First Line Drugs Prescription Volume Forecast (2016-2021)
The US Glaucoma Second Line Drugs Market Forecast by Value (2016-2021)
The US Glaucoma Second Line Drugs Prescription Volume Forecast (2016-2021)
The US MIGS Procedure Volume Forecast (2016-2021)
OUS Glaucoma Drugs Market Forecast by Value (2016-2021)
Global Type 2 Diabetes Patients Population Forecast (2016-2021)
Global Population Older than 60 years (2012-2016)
Global Per Capita Healthcare Expenditure (2012-2016)
Global GDP per Capita (2012-2016)
Global Obese Population (2012-2016)
Drug Approval Process
The US Glaucoma First Line Drugs Market Share by Company (2016/2021)
The US Glaucoma Second Line Drugs Market Share by Company (2016/2021)
The US MIGS Market Share by Company (2016/2021)
Pfizer Inc. Revenue by Segment (2016)
Pfizer Inc.’s Revenue and Net Income (2012-2016)
Pfizer Inc. R&D Expenses (2015-2016)
Novartis AG Net Sales by Segment (2016)
Novartis AG Net Sales and Net Income (2012-2016)
Novartis AG R&D Expenditure (2014-2016)
Merck & Co., Inc. Sales by Segment (2016)
Merck & Co., Inc.’s Sales and Net Income (2012-2016)
Merck & Co., Inc.’s R&D Expenditure (2014-2016)
Allergan Plc. Net Revenue by Segment (2016)
Allergan Plc. Net Revenue and Net Income (2012-2016)
Allergan Plc. R&D Expenditure (2014-2016)
Types of Glaucoma
Treatments Available for Glaucoma
Glaucoma Pharmaceutical Market by Segment
Global Glaucoma Market Forecast by Value (2016-2021)
Global Glaucoma Market by Segments (2016)
Global Glaucoma Drugs Market Forecast by Value (2016-2021)
Global Glaucoma Market by Drug Class (2016)
Global Glaucoma Drugs Market by Region (2016)
Global Glaucoma Patient Volume Forecast (2016-2021)
The US Glaucoma Drugs Market Forecast by Value (2016-2021)
The US Glaucoma Patient Volume Forecast (2016-2021)
The US Open Angle Glaucoma Patient Volume Forecast (2016-2021)
The US Glaucoma Prescription Volume Forecast (2016-2021)
The US Glaucoma Drug Market by Type (2016)
The US Glaucoma First Line Drugs Market Forecast by Value (2016-2021)
The US Glaucoma First Line Drugs Prescription Volume Forecast (2016-2021)
The US Glaucoma Second Line Drugs Market Forecast by Value (2016-2021)
The US Glaucoma Second Line Drugs Prescription Volume Forecast (2016-2021)
The US MIGS Procedure Volume Forecast (2016-2021)
OUS Glaucoma Drugs Market Forecast by Value (2016-2021)
Global Type 2 Diabetes Patients Population Forecast (2016-2021)
Global Population Older than 60 years (2012-2016)
Global Per Capita Healthcare Expenditure (2012-2016)
Global GDP per Capita (2012-2016)
Global Obese Population (2012-2016)
Drug Approval Process
The US Glaucoma First Line Drugs Market Share by Company (2016/2021)
The US Glaucoma Second Line Drugs Market Share by Company (2016/2021)
The US MIGS Market Share by Company (2016/2021)
Pfizer Inc. Revenue by Segment (2016)
Pfizer Inc.’s Revenue and Net Income (2012-2016)
Pfizer Inc. R&D Expenses (2015-2016)
Novartis AG Net Sales by Segment (2016)
Novartis AG Net Sales and Net Income (2012-2016)
Novartis AG R&D Expenditure (2014-2016)
Merck & Co., Inc. Sales by Segment (2016)
Merck & Co., Inc.’s Sales and Net Income (2012-2016)
Merck & Co., Inc.’s R&D Expenditure (2014-2016)
Allergan Plc. Net Revenue by Segment (2016)
Allergan Plc. Net Revenue and Net Income (2012-2016)
Allergan Plc. R&D Expenditure (2014-2016)
LIST OF TABLES
New Glaucoma Drugs and Therapy Devices in Pipeline (2016)
Global Glaucoma Market- Key Companies Revenue & Market Cap Comparison (2016)
Major Product Developments by Pfizer Inc. (Since November 1, 2016)
New Glaucoma Drugs and Therapy Devices in Pipeline (2016)
Global Glaucoma Market- Key Companies Revenue & Market Cap Comparison (2016)
Major Product Developments by Pfizer Inc. (Since November 1, 2016)
